The Impella-EUROSHOCK-registry evaluates the safety and efficacy of the Impella-2.5 percutaneous left ventricular assist device (pLVAD) in patients with CS following AMI.
The present manuscript will review the prognostic value of platelet function testing to identify patients with CAD at risk of bleeding complications and the potential applications of these tests in the modern era of antiplatelet pharmacotherapy.
This suggests that cerebral oximetry is not only useful for neurological but also for hemodynamic monitoring and preoperative risk stratification of cardiac surgery patients.
